MNKD MANNKIND CORP

Nasdaq Pharmaceutical Preparations DE CIK: 0000899460
AI RATING
STRONG_SELL
85% Confidence

Investment Thesis

MannKind is operationally unprofitable with negative stockholders' equity (-$59.2M) and unsustainable cash burn (-$7.2M FCF). Despite 22% revenue growth, the company operates at -18.4% net margin and cannot cover debt service from operations (-0.2x interest coverage), indicating a path toward insolvency unless profitability is achieved imminently.

Strengths

  • + Revenue growing 22.2% YoY shows commercial traction
  • + Adequate short-term liquidity with 1.87x current ratio
  • + Cash reserves of $52.8M provide near-term runway

Risks

  • ! Negative stockholders' equity of -$59.2M indicates technical insolvency
  • ! Operating cash flow negative at -$5.4M; company cannot fund operations from business
  • ! High debt burden of $318.7M with no operational cash to service; interest coverage at -0.2x
  • ! Net margin deteriorating at -18.4%; each dollar of revenue loses 18+ cents
  • ! EPS worsening sharply at -80% YoY decline
  • ! Cash burn rate suggests 4-5 years runway; requires near-term inflection to profitability

Key Metrics to Watch

Financial Metrics

Revenue
90.2M
Net Income
-16.6M
EPS (Diluted)
$-0.05
Free Cash Flow
-7.2M
Total Assets
744.4M
Cash
52.8M

Profitability Ratios

Gross Margin N/A
Operating Margin -1.8%
Net Margin -18.4%
ROE N/A
ROA -2.2%
FCF Margin -8.0%

Balance Sheet & Liquidity

Current Ratio
1.87x
Quick Ratio
1.50x
Debt/Equity
N/A
Debt/Assets
108.0%
Interest Coverage
-0.19x
Long-term Debt
318.7M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-08T11:24:12.675322 | Data as of: 2026-03-31 | Powered by Claude AI